SGX Pharmaceuticals, Inc. - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for SGX Pharmaceuticals, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

SGX Pharmaceuticals, Inc.. The Group's principal activety is to discover, develop & innovative cancer therapeutics. It develops Troxatyl, a novel compound which is currently in a pivotal Phase II/III clinical trial for the third-line treatment of Acute Myelogenous Leukemia, or AML, a blood cancer. Third-line treatment refers to the treatment of patients who have already received two regimens of chemotherapy with the goal of remission. it also developing an internal oncology product pipeline and lead compounds for multiple partners through the application of its proprietary fragment-based drug discovery platform, Fragments of Active Structures. It operates only in United States.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report